Top Markets
#1 EXOD EXOD +22.08%
#2 Ontology Gas Ontology Gas +17.44%
#3 Geodnet Geodnet +17.14%
#4 Derive Derive +16.24%
#5 Neiro Neiro +14.58%
#6 Status Status +13.62%
#7 Pons Pons +12.37%
#8 Collect on Fanable Collect on Fanable +11.77%
#9 AUKI AUKI +9.94%
#10 Curve DAO Curve DAO +9.61%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Rang in aandelen #25370
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Aandeelprijs
$2.63
Marktkapitalisatie
$50.45M
Verandering (1 dag)
-0.98%
Verandering (1 jaar)
78.10%
Land
JP
Handel Carna Biosciences, Inc. (4572)

Categorie

Healthcare
Dividendgeschiedenis van Carna Biosciences, Inc. (4572)
Carna Biosciences, Inc. (aandelsymbool: 4572) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Carna Biosciences, Inc. (4572) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US